Analytical Data
-
Gene name
E & M
- Application
-
Alternative Names
/
-
Species
Severe acute respiratory syndrome coronavirus 2
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0DTC4 & P0DTC5
-
Expression Region
1-42aa
-
Molecular Weight
17.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of E & M recombinant proteins is rooted in the broader context of protein engineering and biotechnology, which aim to leverage the unique properties of proteins for various applications in medicine, industry, and research. E & M proteins, derived from specific genes or organisms, exhibit distinct functionalities that make them valuable for therapeutic and diagnostic purposes. The interest in these proteins has surged due to their potential in vaccine development, particularly in the context of infectious diseases and cancer, where they can trigger targeted immune responses. Furthermore, advancements in recombinant DNA technology have facilitated the production of these proteins in host systems such as bacteria, yeast, or mammalian cells, enhancing their yield and purity for experimental use. Researchers investigate the structural and functional characteristics of E & M proteins to understand their mechanisms of action and to optimize their applications. This research extends beyond basic science, contributing to the development of novel therapeutic strategies and biotechnological innovations. Overall, the exploration of E & M recombinant proteins represents a promising frontier in the intersection of immunology, molecular biology, and biotechnology, addressing critical challenges in health and disease management.
